Cytochrome P450 (CYP) 3A is the primary CYP isoenzyme subfamily responsible for phase I metabolism of Ͼ50% of drug doses administered to humans.
Because the pharmacokinetics of various drugs is influenced by individual variations in CYP3A activity, it is important to evaluate those variations in the clinical setting to achieve the optimum therapeutic outcomes. 9) Probe drugs including midazolam, erythromycin, nifedipine, lidocaine, and dextromethorphan and endogenous compounds such as cortisol and testosterone have been utilized to evaluate CYP3A activity. 10, 11) Watkins 12) proposed three specific CYP3A probes: erythromycin; midazolam; and cortisol. However, the probe drugs available for accurate, safe, and easy measurement of CYP3A activity remain limited.
Lansoprazole, (Ϯ)-2-[[ [3-methyl-4 -(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole, is a proton-pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting (H ϩ /K ϩ )-ATPase and is prescribed commonly for the treatment of gastric ulcer, reflux esophagitis, etc., with few serious side effects reported. Following administration, lansoprazole is extensively metabolized to 5-hydroxylansoprazole and lansoprazole sulfone (LS) by CYP2C19 and CYP3A, respectively. 13) Masa et al. 14) reported that the metabolism to LS by CYP3A occurs independently of that to 5-hydroxylansoprazole by CYP2C19 in the human liver. Inhibition of one metabolic pathway caused by the genetic polymorphisms of CYPs leads to upregulation of another pathway in vivo. To use lansoprazole as probe drug, these problems should be elucidated in vitro or in vivo. The present study investigated the utility of lansoprazole in assessing CYP3A activity in comparison with previously reported in vitro methods. Medicine (Kawasaki, Japan).
MATERIALS AND METHODS

Chemicals
Measurement of Lansoprazole Sulfoxidation Activity in Human Liver Microsomes
Lansoprazole sulfoxidation activity was analyzed in liver microsomes following a previously reported method. 15, 16) Fourteen liver microsomes (0.4 mg) were mixed with lansoprazole 5 mM, ethylenediaminetetraacetic acid (EDTA) 0.5 mM, Na-K phosphate 0.33 M (pH 7.4), and distilled water. The reaction was initiated by addition of an NADPH-generating system (MgCl 2 5 mM, NADP ϩ 0.5 mM, glucose-6-phoshate 5 mM, and 1 unit of glucose-6-phosphate dehydrogenase). The total volume of 1 ml was incubated at 37°C and terminated after 15 min by icing. Then, the mixture was centrifuged at 10000ϫg for 10 min. Diazepam 3.5 mM was added to a 0.9-ml aliquot of the supernatant layer as internal standard and applied to an Oasis HLB extraction cartridge (Waters Co., Milford, MA, U.S.A.) that had previously been activated with 1.0 ml of 100% methanol followed by 1.0 ml of distilled water. The cartridge was then eluted with 1.0 ml of 40% methanol in distilled water. The final extract was eluted from the cartridge with 1.0 ml of 80% methanol. This extract was dried at 60°C for 60 min and stored at Ϫ20°C. The residue was dissolved in 180 ml of 100% methanol with vortex mixing for 30 s then in 180 ml of the mobile phase with vortex mixing for 30 s. The mobile phase consisted of NaClO 4 0.2 M, acetonitrile, and methanol (55 : 23 : 22 v/v/v). One hundred microliters of the solution was injected into the high-performance liquid chromatographic (HPLC) apparatus. The samples were analyzed using a fully automated HPLC system consisting of a DP-8020 pump, an AS-8020 autosampler, and a UV-8020 UV detector (Tosoh Co., Tokyo, Japan). Separation was achieved on a chiral CD-Ph column (4.6 mm I.D.ϫ250 mm, Shiseido Co., Tokyo, Japan). The chromatographic data were collected and processed by LC-8020 multistation system (Tosoh Co.). The flow rate was 0.6 ml/min with column temperature maintained at 30°C. The eluent was monitored at 286 nm using a UV-8020 Intelligent UV Detector (Tosoh Co.). Lansoprazole 5-hydroxylation activity in human microsomes was measured simultaneously.
Measurement of Lansoprazole Sulfoxidation Activity in Human Liver Microsomes Preincubated with Anti-CYP2C19 Antibody Fourteen liver microsomes (0.4 mg) were preincubated with anti-CYP2C19 antibody (40 mg) (BD Biosciences, Woburn, MA, U.S.A.) for 20 min on ice. Thereafter, the samples were reacted with lansoprazole and the NADPH system and analyzed by HPLC following the methods described above.
Measurement of Testosterone 6b b-Hydroxylation Activity in Human Liver Microsomes Testosterone 6b-hydroxylation (T6b-OH) was measured according to the method of Niwa et al. 17) Briefly, the 14 liver microsomes were mixed with testosterone, EDTA, Na-K phosphate, and distilled water. The reaction was initiated by addition of the NADPHgenerating system. Incubation, drying, and storage were performed by the same methods as for the assay of LS activity. The residue was dissolved in 300 ml of mobile phase C with vortex mixing for 30 s. A 100-ml aliquot of the solution was injected into the HPLC apparatus. The samples were analyzed by the fully automated HPLC system. Mobile phase C consisted of acetonitrile and distilled water (1 : 1, v/v). Mobile phase D consisted of acetonitrile and distilled water
The HPLC system consisted of a CCPM-II pump (Tosoh Co.), an AS-8020 autosampler (Tosoh Co.), and a MCPD-3600 UV detector (Otsuka Electronics Co., Osaka, Japan). Separation was achieved on a CAPCELL PACK18 column (4.6 mm I.D.ϫ250 mm, Shiseido Co.). The flow rate was 1.0 ml/min over the 35-min run time at 30°C. The following gradient profile was used, with the percentages indicating the amount of mobile phase C in mobile phase D: tϭ0 min, 0% C; tϭ10 min, 38% C; tϭ17.5 min, 0% C; tϭ35 min, 0% C. The eluent was monitored at 254 nm by a MCPD-3600 UV Detector (Otsuka Electronics Co., Osaka, Japan).
Assay for CYP2C19 Activity CYP2C19 activity was determined as previously described. 18, 19) Briefly, CYP 2C19 enzyme activity was determined using 100 mM S-mephenytoin. The substrate mixture containing 1 mg/ml human liver microsome was incubated at 37°C for 60 min. The reaction was then terminated and subjected to HPLC Gulliver 1500 analysis (Nihonbunko, Tokyo, Japan) with a reversed-phase analytical column.
Immunoblot Analysis of CYP3A SDS-polyacrylamide gel electrophoresis and Western blot analysis were carried out on human liver microsomes, and the immunoblots were probed with antibody to CYP3A4 (BD Gentist TM, Discovery Labware, Inc., BD Biosciences, MA, U.S.A.).
Statistical Analysis Statistical analysis was performed using StatView (ver. 4.58, Abacus, Berkeley, CA, U.S.A.). Parts of data are expressed as meanϮS.E.M. The unpaired, Mann-Whitney U-test was used to determine differences between groups for comparisons of human microsomes preincubated with and without anti-CYP2C19 antibody. Correlations between groups were evaluated using regression analysis. Probability values Ͻ0.05 were considered to represent a statistically significant difference.
RESULTS
Lansoprazole Sulfoxidation and T6b b-OH Activities in
Human Liver Microsomes Lansoprazole sulfoxidation and T6b-OH activities were assessed in 14 human liver microsomes by HPLC. The difference between the highest and lowest lansoprazole sulfoxidation activity ranged from 2.06 to 48.55 nmol/min/mg protein (Fig. 1A) . The range of variation in lansoprazole sulfoxidation activity was approximately 23-fold. On the other hand, the difference between the highest and lowest T6b-OH activity ranged from 0.28 to 5.66 nmol/min/mg proteins (Fig. 1B) . The range of variation in T6b-OH activity was likewise approximately 20-fold. Our data indicate that the pattern of individual variation in LSx activity was similar to that of T6b-OH activity. Lansoprazole sulfoxidation activity was significantly correlated with T6b-OH activity (rϭ0.949, pϽ0.0001) (Fig. 1C) .
Correlation between LSx Activities and CYP3A Protein Levels in Human Liver Microsomes We previously reported that CYP3A activity measured with T6b-OH is well correlated with CYP3A protein level. 20) In this study, we evaluated the correlation between lansoprazole sulfoxidation activity and CYP3A protein level. Lansoprazole sulfoxidation activity was significantly correlated with CYP3A protein level (rϭ0.827, pϽ0.001) (Fig. 2A) . In addition, T6b-OH activity was reconfirmed to correlate with CYP3A protein level (rϭ0.804, pϽ0.001) (Fig. 2B) .
Correlation between Lansoprazole Sulfoxidation and Lansoprazole 5-Hydroxylation Activities in Human Liver
Microsomes Lansoprazole is metabolized to 5-hydroxylansoprazole by CYP2C19, while to LS by CYP3A4. 13) There was no correlation between lansoprazole sulfoxidation activity and lansoprazole 5-hydroxylation activity (rϭ0.088) (Fig. 3A) . Lansoprazole sulfoxidation activity was not correlated with CYP2C19 activity (rϭ0.280) (Fig. 3B) . On the other hand, lansoprazole 5-hydroxylation activity was significantly correlated with CYP2C19 activity (rϭ0.706, pϽ0.05) (Fig. 3C) . This result suggests that the metabolism of lansoprazole to LS by CYP3A occurs independently of metabolism to 5-hydroxylansoprazole by CYP2C19.
Effects of Anti-CYP2C19 Antibody on LSx Activity in Human Liver Microsomes
There was no significant difference between two averages of lansoprazole sulfoxidation activity with and without anti-CYP2C19 antibody (Fig. 4A) . On the other hand, the average of lansoprazole 5-hydroxylation activity with anti-CYP2C19 antibody was decreased in comparison with that without anti-CYP2C19 antibody (Fig.  4B) . Lansoprazole sulfoxidation activity in liver microsomes preincubated with anti-CYP2C19 antibody and T6b-OH activity in liver microsomes are shown in Fig. 4 . Lansoprazole sulfoxidation activity in liver microsomes preincubated with anti-CYP2C19 antibody was significantly correlated with T6b-OH activity (Fig. 4C) (rϭ0.919, pϽ0.0001) . Moreover, we found a significant correlation between lansoprazole sulfoxidation activities in liver microsomes with and without anti-CYP2C19 antibody preincubation (rϭ0.947, pϽ0.0001) (Fig. 4D) . CYP2C19 activity did not affect lansoprazole sulfoxidation activity.
DISCUSSION
In this study, we investigated whether lansoprazole as a new probe drug could be used to assess CYP3A activity. The probe-drug activity of compounds such as erythromycin, midazolam, endogenous cortisol, and testosterone has been already established. 11) Although those compounds have high specificity for measurement of CYP3A activity, difficulties in finding an ideal probe remain due to differences in enzyme activity in organs such as the liver, intestines, and kidney; the overlap of substrate specificity with P-glycoprotein and other CYP enzymes; high interindividual proband variability; and possible low affinity of the enzyme for probe drugs. In addition, these probes require invasive methods to administer the drug and collect the samples. The erythromycin breath test has been widely used. 21) However, this method needs intravenous administration of a radioactive isotope.
11) Although a single dose of 0.025 mg/kg of midazolam is less than a clinical dose (0.15 mg/kg), this drug must be administered intravenously and has central nervous system-inhibitory actions, such as lethargy and inhibition of respiratory function. 22) Therefore intravenous administration of midazolam is not sufficient for measuring CYP3A activity in volunteer subjects. Among proposed non-invasive probes, the urinary secretion of cortisol follows a circadian rhythm and testosterone has sex differences. The ideal probes for pharmacokinetic studies should satisfy both specificity for CYP3A activity and high safety probe for patients. The pharmacokinetics and pharmacodynamics of PPIs including omeprazole and lansoprazole were investigated to establish individualized pharmacotherapy. 23) Recently, Böttiger 24) proposed that omeprazole, another PPI, can be used to assess CYP3A activity. Although omeprazole is metabolized by CYP2C19 and CYP3A4, the metabolism of omeprazole to hydroxylomeprazole via CYP2C19 pathway is 4-fold greater than omeprazole sulfoxydation via the CYP3A pathway. 25) We focused on the metabolic pathway of lansoprazole, which is metabolized almost equally to LS and 5-hydroxylansoprazole by CYP3A and CYP2C19, respectively, which means the contribution of CYP3A4 on lansoprazole metabolism by CYP3A is greater than that of omeprazole. 26) Moreover, it will be important that this metabolic pathway of lansoprazole can be said simple among many PPIs. There are few reports of serious adverse events associated with lansoprazole in various patient populations. Because lansoprazole is both specific and safe, it was adapted as an indicator of CYP3A activity in our study.
To use lansoprazole as a CYP3A probe, the following two points should be clarified. First, does lansoprazole accurately reflect CYP3A activity? Second, is lansoprazole sulfoxidation activity influenced by CYP2C19 activity? We attempted to address these two points. The metabolic pathway of lansoprazole to LS via CYP3A was elucidated. 13) To the best of our knowledge, no experimental lansoprazole sulfoxidation activity data are available comparing the results obtained with typical CYP3A probes. Individual variations of lansoprazole sulfoxidation activity were observed in human liver microsomes. The range of variation in lansoprazole sulfoxidation activity was approximately 20-fold. T6b-OH activity is a typical indicator of CYP3A activity in human liver microsomes. 27) Lansoprazole sulfoxidation activities were compared with T6b-OH activities in 14 human liver microsomes. The pattern of individual variations in T6b-OH activity was similar to that of lansoprazole sulfoxidation activity. Lansoprazole sulfoxidation activity was significantly positively correlated with T6b-OH activity. In addition, lansoprazole sulfoxidation activity was correlated with CYP3A protein level. Our results suggest that lansoprazole sulfoxidation activity accurately reflects CYP3A activity in the human liver.
Furthermore, we investigated whether lansoprazole sulfoxidation activity in human liver microsomes is affected by lansoprazole 5-hydroxylation activity through the CYP2C19 metabolic pathway. Lansoprazole sulfoxidation activity was not correlated with lansoprazole 5-hydroxylation activity and CYP2C19 activity. On the other hand, lansoprazole 5-hydroxylation activity was significantly correlated with CYP2C19 activity.
When human liver microsomes were preincubated with anti-CYP2C19 antibody at a dose of 40 mg so as to block CYP2C19 activity, lansoprazole sulfoxidation was closely correlated with T6b-OH activity in liver microsomes after anti-CYP2C19 antibody treatment. Consequently, we found that there was a significant correlation between lansoprazole sulfoxidation activities with or without anti-CYP2C19 antibody. LS can thus be used as a marker for CYP3A activity, and is not involved in CYP2C19 activity in human liver microsomes in vitro. Measurement of lansoprazole and its metabolites with the method we used is very sensitive and useful both in human liver microsomes and blood. Use of lansoprazole as probe drug of human hepatic CYP3A activity must be readily available in vivo. In our previous study, we demonstrated that plasma concentration of lansoprazole and its metabolites was measurable oral administration of lansoprazole at a dose of 30 mg in healthy subjects, reflecting human hepatic CYP3A activity. 28) Furthermore, the plasma concentration of LS was confirmed to correlate with 6b-hydroxycortisol, a known marker of CYP 3A activity in healthy subjects. 28) Pauli-Magnus et al. 29) reported that lansoprazole is a substrate and inhibitor of P-glycoprotein. The pharmacokinetics of lansoprazole may be affected by P-glycoprotein activity or MDR-1 genotypes. We will further elucidate the influence of transporters such as P-glycoprotein on CYP 3A metabolism, although lansoprazole is a good indicator for CYP3A activity in studies both in vivo and in vitro. Furthermore, lansoprazole can simultaneously assess CYP3A and CYP2C19.
In conclusion, lansoprazole as a probe drug for CYP3A activity was assessed in vitro. Pending more extensive evaluation, LS has the potential to be utilized as a marker for CYP3A activity, allowing accurate, easy, and safe measurement.
